$IMMB .213 Immunotech Laboratories, Inc. Announc
Post# of 144481
[b]$IMMB[/b] .213 Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc.
PASADENA, CA, [b][color=blue]Feb 19, 2013[/color][/b] (MARKETWIRE via COMTEX) -- A research report has been issued by Market Advisors, Inc. "Fundamental Analysis for Today's Investments" on Immunotech Laboratories, Inc (PINKSHEETS: IMMB).
According to the report, Immunotech Laboratories Inc. is committed to beginning clinical trials for its patented IPF Technology to treat HIV/AIDS, Cancer and Hepatitis C. Treatments for HIV/AIDS and cancer and other diseases are always welcome news and this Company appears to have some answers for these health problems which we are all being confronted with, not just here is the U.S., but globally. Immunotech Laboratories Inc. has started restructuring and has added new board members with a goal of up-listing to NASDAQ.
To see the full report please click here (http://freepdfhosting.com/7bd113ff01.pdf).
The report will also be available soon on the Immunotech Company website immunotechlab.com.
About Immunotech Laboratories, Inc.
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. Please visit the company website at Immunotechlab.com and see testimonials of treated patients at lifechoicemx.com
About Market Advisors, Inc. Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron's, Forbes Magazine and The Dick Davis Digest to name a few.
(0)
(0)